[Federal Register Volume 84, Number 166 (Tuesday, August 27, 2019)]
[Rules and Regulations]
[Pages 44703-44708]
[FR Doc No: 2019-18366]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2018-0526; FRL-9998-22]

Sedaxane; Pesticide Tolerances

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This regulation establishes a tolerance for residues of
sedaxane in or on legume vegetables (dried or succulent), crop group 6.
Syngenta Crop Protection, LLC requested this tolerance under the
Federal Food, Drug, and Cosmetic Act (FFDCA).

DATES: This regulation is effective August 27, 2019. Objections and
requests for hearings must be received on or before October 28, 2019,
and must

be filed in accordance with the instructions provided in 40 CFR part
178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).

ADDRESSES: The docket for this action, identified by docket
identification (ID) number EPA-HQ-OPP-2018-0526, is available at http://www.regulations.gov or at the Office of Pesticide Programs Regulatory
Public Docket (OPP Docket) in the Environmental Protection Agency
Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334,
1301 Constitution Ave. NW, Washington, DC 20460-0001. The Public
Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through
Friday, excluding legal holidays. The telephone number for the Public
Reading Room is<PHONE_NUMBER>, and the telephone number for the OPP
Docket is<PHONE_NUMBER>. Please review the visitor instructions and
additional information about the docket available at http://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Michael Goodis, Registration Division
(7505P), Office of Pesticide Programs, Environmental Protection Agency,
1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; main telephone
number:<PHONE_NUMBER>; email address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
The following list of North American Industrial Classification System
(NAICS) codes is not intended to be exhaustive, but rather provides a
guide to help readers determine whether this document applies to them.
Potentially affected entities may include:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).

B. How can I get electronic access to other related information?

    You may access a frequently updated electronic version of EPA's
tolerance regulations at 40 CFR part 180 through the Government
Printing Office's e-CFR site at http://www.ecfr.gov/cgi-bin/text-idx?&c=ecfr&tpl=/ecfrbrowse/Title40/40tab_02.tpl.

C. How can I file an objection or hearing request?

    Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an
objection to any aspect of this regulation and may also request a
hearing on those objections. You must file your objection or request a
hearing on this regulation in accordance with the instructions provided
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify
docket ID number EPA-HQ-OPP-2018-0526 in the subject line on the first
page of your submission. All objections and requests for a hearing must
be in writing and must be received by the Hearing Clerk on or before
October 28, 2019. Addresses for mail and hand delivery of objections
and hearing requests are provided in 40 CFR 178.25(b).
    In addition to filing an objection or hearing request with the
Hearing Clerk as described in 40 CFR part 178, please submit a copy of
the filing (excluding any Confidential Business Information (CBI)) for
inclusion in the public docket. Information not marked confidential
pursuant to 40 CFR part 2 may be disclosed publicly by EPA without
prior notice. Submit the non-CBI copy of your objection or hearing
request, identified by docket ID number EPA-HQ-OPP-2018-0526, by one of
the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be CBI or other
information whose disclosure is restricted by statute.
     Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW, Washington, DC
20460-0001.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.html.
    Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at http://www.epa.gov/dockets.

II. Summary of Petitioned-For Tolerance

    In the Federal Register of February 6, 2019 (84 FR 2115) (FRL-9987-
08), EPA issued a document pursuant to FFDCA section 408(d)(3), 21
U.S.C. 346a(d)(3), announcing the filing of a pesticide petition (PP
8F8679) by Syngenta Crop Protection, LLC, P.O. Box 18300, Greenboro, NC
27419. The petition requested that 40 CFR 180.665 be amended by
establishing a tolerance for residues resulting from seed treatment
uses of the fungicide sedaxane, in or on legume vegetables (dried or
succulent), crop group 6 at 0.01 parts per million (ppm) and to remove
the existing tolerances for soybean, seed at 0.01 ppm and pea and bean,
dried shelled, except soybean, subgroup 6C at 0.01 ppm upon
establishment of the group 6 tolerance. That document referenced a
summary of the petition prepared by Syngenta, which is available in the
docket, http://www.regulations.gov. There were no comments received in
response to the notice of filing.

III. Aggregate Risk Assessment and Determination of Safety

    Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a
tolerance (the legal limit for a pesticide chemical residue in or on a
food) only if EPA determines that the tolerance is ``safe.'' Section
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a
reasonable certainty that no harm will result from aggregate exposure
to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable
information.'' This includes exposure through drinking water and in
residential settings but does not include occupational exposure.
Section 408(b)(2)(C) of FFDCA requires EPA to give special
consideration to exposure of infants and children to the pesticide
chemical residue in establishing a tolerance and to ``ensure that there
is a reasonable certainty that no harm will result to infants and
children from aggregate exposure to the pesticide chemical residue. . .
.''
    Consistent with FFDCA section 408(b)(2)(D), and the factors
specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available
scientific data and other relevant information in support of this
action. EPA has sufficient data to assess the hazards of and to make a
determination on aggregate exposure for sedaxane including exposure
resulting from the tolerances established by this action. EPA's
assessment of exposures and risks associated with sedaxane follows.

A. Toxicological Profile

    EPA has evaluated the available toxicity data and considered its
validity, completeness, and reliability as well as the relationship of
the results of the studies to human risk. EPA has also considered
available information concerning the variability of the sensitivities
of major identifiable subgroups of consumers, including infants and
children.

    The main target tissue for sedaxane is the liver. Sedaxane also
caused thyroid hypertrophy/hyperplasia in male rats. In the acute
neurotoxicity (ACN) and sub-chronic neurotoxicity (SCN) studies,
sedaxane caused decreased activity, muscle tone, rearing and grip
strength; however, no adverse histopathology was observed, and EPA has
concluded that there is low concern for neurotoxicity.
    In the rat, no adverse effects in fetuses were seen in
developmental toxicity studies at maternally toxic doses. In the
rabbit, fetal toxicity was observed at the same doses as the dams.
Offspring effects in the rat reproduction study occurred at the same
doses causing parental effects.
    The available data show evidence of liver tumors (in male rats and
mice), thyroid tumors (in male rats), and uterine tumors (in female
rats) resulting from exposure to sedaxane. Based on a weight of
evidence of the available data, a constitutive androstane receptor/
pregnane-X receptor (CAR/PXR)-mediated mitogenic mode-of action (MOA)
was established for liver tumors in male mice and rats and a liver-
mediated altered thyroid hormone homeostasis MOA was established for
thyroid tumors in male rats. At this time, a MOA for the uterine tumors
has not been identified.
    To quantitatively assess the carcinogenic potential of sedaxane,
EPA has concluded that a non-linear approach (i.e., reference dose
(RfD)) is appropriate for the following reasons: (1) There is a clear
understanding of the threshold (non-linear) doses associated with the
key events in the established MOAs leading to liver and thyroid tumors
in rodents, the key events occur only at doses that well exceed the
chronic reference dose (0.11 mg/kg/day); (2) Sedaxane is not mutagenic
or genotoxic; (3) The dose at which uterine tumors was observed is at
261 mg/kg/day, which greatly exceeds the chronic reference dose (0.11
mg/kg/day) being used to assess chronic exposure to sedaxane.
    Sedaxane has low acute toxicity by the oral, dermal, and inhalation
routes. It is not a dermal sensitizer, causes no skin irritation and
only slight eye irritation.
    Specific information on the studies received and the nature of the
adverse effects caused by sedaxane as well as the no-observed-adverse-
effect-level (NOAEL) and the lowest-observed-adverse-effect-level
(LOAEL) from the toxicity studies are discussed in the final rule
published in the Federal Register of December 8, 2017 (82 FR 57867)
(FRL-9970-04).

B. Toxicological Points of Departure/Levels of Concern

    Once a pesticide's toxicological profile is determined, EPA
identifies toxicological points of departure (POD) and levels of
concern to use in evaluating the risk posed by human exposure to the
pesticide. For hazards that have a threshold below which there is no
appreciable risk, the toxicological POD is used as the basis for
derivation of reference values for risk assessment. PODs are developed
based on a careful analysis of the doses in each toxicological study to
determine the NOAEL and the LOAEL. Uncertainty/safety factors are used
in conjunction with the POD to calculate a safe exposure level--
generally referred to as a population-adjusted dose (PAD) or a RfD--and
a safe margin of exposure (MOE). For non-threshold risks, the Agency
assumes that any amount of exposure will lead to some degree of risk.
Thus, the Agency estimates risk in terms of the probability of an
occurrence of the adverse effect expected in a lifetime. For more
information on the general principles EPA uses in risk characterization
and a complete description of the risk assessment process, see http://www.epa.gov/pesticides/factsheets/riskassess.htm.
    A summary of the toxicological endpoints for sedaxane used for
human risk assessment is discussed in Unit III.B. of the final rule
published in the Federal Register of December 8, 2017 (82 FR 57867)
(FRL-9970-04).

C. Exposure Assessment

    1. Dietary exposure from food and feed uses. In evaluating dietary
exposure to sedaxane, EPA considered exposure under the petitioned-for
tolerances as well as all existing sedaxane tolerances in 40 CFR
180.665. EPA assessed dietary exposures from sedaxane in food as
follows:
    i. Acute exposure. Quantitative acute dietary exposure and risk
assessments are performed for a food-use pesticide, if a toxicological
study has indicated the possibility of an effect of concern occurring
as a result of a 1-day or single exposure.
    Such effects were identified for sedaxane. In estimating acute
dietary exposure, EPA used food consumption information from the United
States Department of Agriculture (USDA) under the Nationwide Continuing
Surveys of Food Intake by Individuals (CSFII) and the CDC under the
National Health and Nutrition Examination Survey What We Eat in America
(NHANES/WWEIA) 2003-2008. As to residue levels in food, EPA assumed
tolerance-level residues for all commodities and 100% crop treated.
Default processing factors were used with the exception of peanut
butter which uses empirical processing data.
    ii. Chronic exposure. In conducting the chronic dietary exposure
assessment EPA used the food consumption data from the USDA NHANES/WEIA
2003-2008. As to residue levels in food, EPA assumed tolerance-level
residues for all commodities and 100% crop treated (CT). Default
processing factors were used with the exception of peanut butter which
uses empirical processing data.
    iii. Cancer. Based on the data summarized in Unit III.A., EPA has
concluded that a nonlinear RfD approach is appropriate for assessing
cancer risk to sedaxane. Cancer risk was assessed using the same
exposure estimates as discussed in Unit III.C.1.ii.
    iv. Anticipated residue and percent crop treated (PCT) information.
EPA did not use anticipated residue and/or PCT information in the
dietary assessment for sedaxane. Tolerance-level residues and/or 100%
CT were assumed for all food commodities.
    2. Dietary exposure from drinking water. The Agency used screening
level water exposure models in the dietary exposure analysis and risk
assessment for sedaxane in drinking water. These simulation models take
into account data on the physical, chemical, and fate/transport
characteristics of sedaxane. Further information regarding EPA drinking
water models used in pesticide exposure assessment can be found at
http://www.epa.gov/oppefed1/models/water/index.htm.
    Based on the First Index Reservoir Screening Tool (FIRST) and
Pesticide Root Zone Model Ground Water (PRZM GW), the estimated
drinking water concentrations (EDWCs) of sedaxane for acute exposures
are estimated to be 4.1 parts per billion (ppb) for surface water and
15.1 ppb for ground and for chronic exposures for non-cancer
assessments are estimated to be 1.2 ppb for surface water and 13.0 ppb
for ground water.
    Modeled estimates of drinking water concentrations were directly
entered into the dietary exposure model. For acute dietary risk
assessment, the water concentration value of 15.1 ppb was used to
assess the contribution to drinking water. For chronic dietary risk
assessment, the water concentration of value 13.0 ppb was used to
assess the contribution to drinking water.
    3. From non-dietary exposure. The term ``residential exposure'' is
used in this document to refer to non-occupational, non-dietary
exposure (e.g., for lawn and garden pest control, indoor pest control,
termiticides, and

flea and tick control on pets). Sedaxane is not registered for any
specific use patterns that would result in residential exposure.
    4. Cumulative effects from substances with a common mechanism of
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when
considering whether to establish, modify, or revoke a tolerance, the
Agency consider ``available information'' concerning the cumulative
effects of a particular pesticide's residues and ``other substances
that have a common mechanism of toxicity.''
    Unlike other pesticides for which EPA has followed a cumulative
risk approach based on a common mechanism of toxicity, EPA has not made
a common mechanism of toxicity finding as to sedaxane and any other
substances, and sedaxane does not appear to produce a toxic metabolite
produced by other substances. For the purposes of this tolerance
action, therefore, EPA has assumed that sedaxane does not have a common
mechanism of toxicity with other substances. For information regarding
EPA's efforts to determine which chemicals have a common mechanism of
toxicity and to evaluate the cumulative effects of such chemicals, see
EPA's website at https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/cumulative-assessment-risk-pesticides.

D. Safety Factor for Infants and Children

    1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA
shall apply an additional tenfold (10X) margin of safety for infants
and children in the case of threshold effects to account for prenatal
and postnatal toxicity and the completeness of the database on toxicity
and exposure unless EPA determines based on reliable data that a
different margin of safety will be safe for infants and children. This
additional margin of safety is commonly referred to as the FQPA Safety
Factor (SF). In applying this provision, EPA either retains the default
value of 10X, or uses a different additional safety factor when
reliable data available to EPA support the choice of a different
factor.
    2. Prenatal and postnatal sensitivity. There is no evidence for
increased susceptibility following prenatal or post-natal exposures to
sedaxane based on effects seen in developmental toxicity studies in
rabbits or rats. In range-finding and definitive developmental toxicity
studies in rats, neither quantitative nor qualitative evidence of
increased susceptibility of fetuses to in utero exposure to sedaxane
was observed. In these studies, there were no single-dose effects.
There was no evidence of increased susceptibility in a 2-generation
reproduction study in rats following prenatal or post-natal exposure to
sedaxane. Clear NOAELs/LOAELs were established for the developmental
effects seen in rats and rabbits as well as for the offspring effects
seen in the 2-generation reproduction study. The dose-response
relationship for the effects of concern is well characterized.
    3. Conclusion. EPA has determined that reliable data show the
safety of infants and children would be adequately protected if the
FQPA SF were reduced to 1X. That decision is based on the following
findings:
    i. The toxicity database for sedaxane is complete.
    ii. Given the available information, there is low concern that
sedaxane is a neurotoxic chemical and there is no need for a
developmental neurotoxicity study or additional uncertainty factors
(UFs) to account for neurotoxicity.
    iii. In the rat, no adverse effects in fetuses were seen in
developmental toxicity studies at maternally toxic doses. In the
rabbit, fetal toxicity was observed at the same doses as the dam
(increased unossified sternebrae and 13th rudimentary ribs, a decrease
in fetal weights of 9% and increased abortions). In the dam, at the
same doses, the effects were decreased body weight, reduced food
consumption, and decreased defecation. In reproduction studies,
offspring effects occurred at the same doses causing parental effects;
thus, there was no quantitative or qualitative increase in sensitivity
in rat pups. The LOAELs and NOAELs for the developmental and
reproduction studies were clearly defined. The NOAEL used for the acute
dietary risk assessment (30 mg/kg/day), based on effects observed in
the ACN study, is protective of the developmental and offspring effects
seen in rabbits and rats with the NOAELs of 100-200 mg/kg/day. Based on
these considerations, there are no residual uncertainties for pre-and/
or post-natal susceptibility.
    iv. There are no residual uncertainties identified in the exposure
databases. The dietary food exposure assessments were performed based
on 100% CT and tolerance-level residues. EPA made conservative
(protective) assumptions in the ground and surface water modeling used
to assess exposure to sedaxane in drinking water. These assessments
will not underestimate the exposure and risks posed by sedaxane.

E. Aggregate Risks and Determination of Safety

    EPA determines whether acute and chronic dietary pesticide
exposures are safe by comparing aggregate exposure estimates to the
acute PAD (aPAD) and chronic PAD (cPAD). For linear cancer risks, EPA
calculates the lifetime probability of acquiring cancer given the
estimated aggregate exposure. Short-, intermediate-, and chronic-term
risks are evaluated by comparing the estimated aggregate food, water,
and residential exposure to the appropriate PODs to ensure that an
adequate MOE exists.
    1. Acute risk. Using the exposure assumptions discussed in this
unit for acute exposure, the acute dietary exposure from food and water
to sedaxane will occupy <1% of the aPAD for all infants (<1-year-old),
the population group receiving the greatest exposure.
    2. Chronic risk. Using the exposure assumptions described in this
unit for chronic exposure, EPA has concluded that chronic exposure to
sedaxane from food and water will utilize <1% of the cPAD for all
population subgroups the population group receiving the greatest
exposure. There are no residential uses for sedaxane.
    3. Short-term risk. Short-term aggregate exposure takes into
account short-term residential exposure plus chronic exposure to food
and water (considered to be a background exposure level). Because there
are no proposed or registered residential uses of sedaxane a short-term
risk assessment was not performed. The chronic risk assessment is
protective for any short-term exposures from food and drinking water.
    4. Intermediate-term risk. Intermediate-term aggregate exposure
takes into account intermediate-term residential exposure plus chronic
exposure to food and water (considered to be a background exposure
level). Because there are no proposed or registered residential uses of
sedaxane, an intermediate-term risk assessment was not performed. The
chronic assessment is protective for any intermediate-term exposures
from food and drinking water.
    5. Aggregate cancer risk for U.S. population. As discussed in Unit
III.A., EPA has concluded that using the nonlinear approach based on
the chronic RfD will be protective of potential carcinogenicity.
Because the chronic risk is below the Agency's level of concern, EPA
concludes there is no aggregate cancer risk from exposure to sedaxane.

    6. Determination of safety. Based on these risk assessments, EPA
concludes that there is a reasonable certainty that no harm will result
to the general population, or to infants and children from aggregate
exposure to sedaxane residues.

IV. Other Considerations

A. Analytical Enforcement Methodology

    An adequate analytical method is available to enforce the proposed
tolerances for sedaxane in plant commodities. A modification of the
Quick, Easy, Cheap, Effective, Rugged, and Safe (QuEChERS) method was
developed for the determination of residues of sedaxane (as its isomers
SYN508210 and SYN508211) in/on various crops. The sedaxane isomers
(SYN508210 and SYN508211) are quantitatively determined by LC/MS/MS.
The validated limit of quantitation (LOQ) reported in the method is
0.005 ppm for each sedaxane isomer.
    The method may be requested from: Chief, Analytical Chemistry
Branch, Environmental Science Center, 701 Mapes Rd., Ft. Meade, MD
20755-5350; telephone number:<PHONE_NUMBER>; email address:
<EMAIL_ADDRESS>
B. International Residue Limits

    In making its tolerance decisions, EPA seeks to harmonize U.S.
tolerances with international standards whenever possible, consistent
with U.S. food safety standards and agricultural practices. EPA
considers the international maximum residue limits (MRLs) established
by the Codex Alimentarius Commission (Codex), as required by FFDCA
section 408(b)(4). The Codex Alimentarius is a joint United Nations
Food and Agriculture Organization/World Health Organization food
standards program, and it is recognized as an international food safety
standards-setting organization in trade agreements to which the United
States is a party. EPA may establish a tolerance that is different from
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain
the reasons for departing from the Codex level.
    The Codex has not established an MRL for sedaxane in or on the
legume vegetables crop grouping.

V. Conclusion

    Therefore, tolerances are established for residues of sedaxane in
or on vegetable, legume, group 6 at 0.01 ppm. In addition, the Agency
is removing the existing tolerances for pea and bean, dried shelled,
except soybean, subgroup 6C, and soybean seed as they are unnecessary
upon the establishment of the group 6 tolerance.

VI. Statutory and Executive Order Reviews

    This action establishes tolerances under FFDCA section 408(d) in
response to a petition submitted to the Agency. The Office of
Management and Budget (OMB) has exempted these types of actions from
review under Executive Order 12866, entitled ``Regulatory Planning and
Review'' (58 FR 51735, October 4, 1993). Because this action has been
exempted from review under Executive Order 12866, this action is not
subject to Executive Order 13211, entitled ``Actions Concerning
Regulations That Significantly Affect Energy Supply, Distribution, or
Use'' (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled
``Protection of Children from Environmental Health Risks and Safety
Risks'' (62 FR 19885, April 23, 1997), nor is it considered a
regulatory action under Executive Order 13771, entitled ``Reducing
Regulations and Controlling Regulatory Costs'' (82 FR 9339, February 3,
2017). This action does not contain any information collections subject
to OMB approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501
et seq.), nor does it require any special considerations under
Executive Order 12898, entitled ``Federal Actions to Address
Environmental Justice in Minority Populations and Low-Income
Populations'' (59 FR 7629, February 16, 1994).
    Since tolerances and exemptions that are established on the basis
of a petition under FFDCA section 408(d), such as the tolerance in this
final rule, do not require the issuance of a proposed rule, the
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et
seq.), do not apply.
    This action directly regulates growers, food processors, food
handlers, and food retailers, not States or tribes, nor does this
action alter the relationships or distribution of power and
responsibilities established by Congress in the preemption provisions
of FFDCA section 408(n)(4). As such, the Agency has determined that
this action will not have a substantial direct effect on States or
tribal governments, on the relationship between the national government
and the States or tribal governments, or on the distribution of power
and responsibilities among the various levels of government or between
the Federal Government and Indian tribes. Thus, the Agency has
determined that Executive Order 13132, entitled ``Federalism'' (64 FR
43255, August 10, 1999) and Executive Order 13175, entitled
``Consultation and Coordination with Indian Tribal Governments'' (65 FR
67249, November 9, 2000) do not apply to this action. In addition, this
action does not impose any enforceable duty or contain any unfunded
mandate as described under Title II of the Unfunded Mandates Reform Act
(UMRA) (2 U.S.C. 1501 et seq.).
    This action does not involve any technical standards that would
require Agency consideration of voluntary consensus standards pursuant
to section 12(d) of the National Technology Transfer and Advancement
Act (NTTAA) (15 U.S.C. 272 note).

VII. Congressional Review Act

    Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.),
EPA will submit a report containing this rule and other required
information to the U.S. Senate, the U.S. House of Representatives, and
the Comptroller General of the United States prior to publication of
the rule in the Federal Register. This action is not a ``major rule''
as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

    Environmental protection, Administrative practice and procedure,
Agricultural commodities, Pesticides and pests, Reporting and
recordkeeping requirements.

    Dated: August 16, 2019.
Daniel Rosenblatt,
Acting Director, Registration Division, Office of Pesticide Programs.
    Therefore, 40 CFR chapter I is amended as follows:

PART 180--[AMENDED]

0
1. The authority citation for part 180 continues to read as follows:

    Authority:  21 U.S.C. 321(q), 346a and 371.

0
2. In Sec.  180.665, amend the table in paragraph (a) as follows:
0
i. Remove the entry for ``Pea and bean, dried shelled, except soybean,
subgroup 6C''; and
0
ii. Add alphabetically the entry ``Vegetable, legume, group 6''.
    The addition reads as follows:

Sec.  180.665  Sedaxane; tolerances for residues.

    (a) * * *

------------------------------------------------------------------------
                                                               Parts per
                          Commodity                             million
------------------------------------------------------------------------

                                * * * * *
Vegetable, legume, group 6..................................        0.01
------------------------------------------------------------------------

* * * * *
[FR Doc. 2019-18366 Filed 8-26-19; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register Volume 81, Number 122 (Friday, June 24, 2016)]
[Notices]
[Page 41368]
[FR Doc No: 2016-14931]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[SEC File No. 270-116, OMB Control No. 3235-0109]

Submission for OMB Review; Comment Request

Upon Written Request Copies Available From: Securities and Exchange
Commission, Office of FOIA Services, 100 F Street NE., Washington, DC
20549-2736.

    Extensions: Rule 12d1-3.

    Notice is hereby given that, pursuant to the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.), the Securities and Exchange
Commission (``Commission'') has submitted to the Office of Management
and Budget this request for extension of the previously approved
collection of information discussed below.
    Exchange Act Rule 12d1-3 (17 CFR 240.12d1-3) requires a
certification that a security has been approved by an exchange for
listing and registration pursuant to Section 12(d) of the Securities
Exchange Act of 1934 (15 U.S.C. 78l(d)) to be filed with the
Commission. The information required under Rule 12d1-3 must be filed
with the Commission and is publicly available. We estimate that it
takes approximately one-half hour to provide the information required
under Rule 12d1-3 and that the information is filed by approximately
688 respondents annually for a total annual reporting burden of 344
burden hours (0.5 hours per response x 688 responses).
    An agency may not conduct or sponsor, and a person is not required
to respond to, a collection of information unless it displays a
currently valid control number.
    The public may view the background documentation for this
information collection at the following Web site, www.reginfo.gov.
Comments should be directed to: (i) Desk Officer for the Securities and
Exchange Commission, Office of Information and Regulatory Affairs,
Office of Management and Budget, Room 10102, New Executive Office
Building, Washington, DC 20503, or by sending an email to:
<EMAIL_ADDRESS>and (ii) Pamela Dyson, Director/Chief
Information Officer, Securities and Exchange Commission, c/o Remi
Pavlik-Simon, 100 F Street NE., Washington, DC 20549 or send an email
to<EMAIL_ADDRESS>Comments must be submitted to OMB within 30
days of this notice.

    Dated: June 20, 2016.
Robert W. Errett,
Deputy Secretary.
[FR Doc. 2016-14931 Filed 6-23-16; 8:45 am]
 BILLING CODE 8011-01-P


[Federal Register Volume 79, Number 93 (Wednesday, May 14, 2014)]
[Notices]
[Pages 27598-27599]
[FR Doc No: 2014-11094]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CD14-19-000]

City of Corvallis, Oregon; Notice of Preliminary Determination of
a Qualifying Conduit Hydropower Facility and Soliciting Comments and
Motions To Intervene

    On April 24, 2014, City of Corvallis, Oregon filed a notice of
intent to construct a qualifying conduit hydropower facility, pursuant
to section 30 of the Federal Power Act (FPA), as amended by section 4
of the Hydropower Regulatory Efficiency Act of 2013 (HREA). The
proposed City of Corvallis Rock Creek Water Treatment Plant Hydropower
Project would have an installed capacity of 28 kilowatts (kW) and would
utilize an existing 16-inch diameter water supply pipeline. The project
would be located near the City of Corvallis in Benton County, Oregon.
    Applicant Contact: Brian Tingwood, City of Corvallis, Oregon, P.O.
Box 1083, Corvallis, OR 97339, Phone No.<PHONE_NUMBER>.
    FERC Contact: Robert Bell, Phone No.<PHONE_NUMBER>, email:
<EMAIL_ADDRESS>    Qualifying Conduit Hydropower Facility Description: The proposed
project would consist of: (1) A proposed 12-inch-diameter bifurcation
pipe, (2) a proposed 4-foot-long, 12-inch-diameter intake pipe; (3) a
proposed powerhouse containing one generating unit with an installed
capacity of 28 kW; (4) a proposed 10-foot-long, 12-inch-diameter
discharge pipe back into the main pipeline; and (5) appurtenant
facilities. The proposed project would have an estimated annual
generating capacity of 219.113 megawatt-hours.
    A qualifying conduit hydropower facility is one that is determined
or deemed to meet all of the criteria shown in the table below.

      Table 1--Criteria for Qualifying Conduit Hydropower Facility
------------------------------------------------------------------------
      Statutory provision              Description       Satisfies (Y/N)
------------------------------------------------------------------------
FPA 30(a)(3)(A), as amended by   The conduit the                      Y
 HREA.                            facility uses is a
                                  tunnel, canal,
                                  pipeline, aqueduct,
                                  flume, ditch, or
                                  similar manmade water
                                  conveyance that is
                                  operated for the
                                  distribution of water
                                  for agricultural,
                                  municipal, or
                                  industrial
                                  consumption and not
                                  primarily for the
                                  generation of
                                  electricity.
FPA 30(a)(3)(C)(i), as amended   The facility is                      Y
 by HREA.                         constructed,
                                  operated, or
                                  maintained for the
                                  generation of
                                  electric power and
                                  uses for such
                                  generation only the
                                  hydroelectric
                                  potential of a non-
                                  federally owned
                                  conduit.
FPA 30(a)(3)(C)(ii), as amended  The facility has an                  Y
 by HREA.                         installed capacity
                                  that does not exceed
                                  5 megawatts.
FPA 30(a)(3)(C)(iii), as         On or before August 9,               Y
 amended by HREA.                 2013, the facility is
                                  not licensed, or
                                  exempted from the
                                  licensing
                                  requirements of Part
                                  I of the FPA.
------------------------------------------------------------------------

    Preliminary Determination: Based upon the above criteria,
Commission staff preliminarily determines that the proposal satisfies
the requirements for a qualifying conduit hydropower facility, which is
not required to be licensed or exempted from licensing.
    Comments and Motions to Intervene: Deadline for filing comments
contesting whether the facility meets the qualifying criteria is 45
days from the issuance date of this notice.
    Deadline for filing motions to intervene is 30 days from the
issuance date of this notice.
    Anyone may submit comments or a motion to intervene in accordance
with the requirements of Rules of Practice and Procedure, 18 CFR
385.210 and 385.214. Any motions to intervene must be received on or
before the specified deadline date for the particular proceeding.
    Filing and Service of Responsive Documents: All filings must (1)
bear in all capital letters the ``COMMENTS CONTESTING QUALIFICATION FOR
A CONDUIT HYDROPOWER FACILITY'' or ``MOTION TO INTERVENE,'' as
applicable; (2) state in the heading the name of the applicant and the
project number of the application to which the filing responds; (3)
state the name, address, and telephone number of the person filing; and
(4) otherwise comply with the requirements of sections 385.2001 through
385.2005 of the Commission's regulations.\1\ All comments contesting
Commission staff's preliminary determination that the facility meets
the qualifying criteria must set forth their evidentiary basis.
---------------------------------------------------------------------------

    \1\ 18 CFR 385.2001-2005 (2013).
---------------------------------------------------------------------------

    The Commission strongly encourages electronic filing. Please file
motions to intervene and comments using the Commission's eFiling system
at http://www.ferc.gov/docs-filing/efiling.asp. Commenters can submit
brief comments up to 6,000 characters, without prior registration,
using the eComment system at http://www.ferc.gov/docs-filing/ecomment.asp. You must include your name and contact information at the
end of your comments. For assistance, please contact FERC Online
Support at<EMAIL_ADDRESS>(866) 208-3676 (toll free), or
(202) 502-8659 (TTY). In lieu of electronic filing, please send a paper
copy to: Secretary, Federal Energy Regulatory Commission, 888 First
Street NE., Washington, DC 20426. A copy of all other filings in
reference to this application must be accompanied by proof of service
on all persons listed in the service list prepared by the Commission in
this proceeding, in accordance with 18 CFR 4.34(b) and 385.2010.
    Locations of Notice of Intent: Copies of the notice of intent can
be obtained directly from the applicant or such copies can be viewed
and reproduced at the Commission in its Public Reference Room, Room 2A,
888 First Street NE., Washington, DC 20426. The filing may also be
viewed on the web at http://www.ferc.gov/docs-filing/elibrary.asp using
the ``eLibrary'' link. Enter the docket number (e.g., CD14-19-000) in
the docket number field to access the document. For assistance, call
toll-free 1-866-208-3676 or email<EMAIL_ADDRESS>For TTY,
call<PHONE_NUMBER>.

    Dated: May 8, 2014.
Kimberly D. Bose,
Secretary.
[FR Doc. 2014-11094 Filed 5-13-14; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register: March 17, 2010 (Volume 75, Number 51)]
[Notices]
[Page 12756-12758]
[DOCID:fr17mr10-77]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0110]

Agency Information Collection Activities: Proposed Collection;
Comment Request; Prescription Drug Advertisements

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on the reporting requirements, including third
party disclosure, contained in FDA's regulations on prescription drug
advertisements.

DATES: Submit written or electronic comments on the collection of
information by May 17, 2010.

ADDRESSES: Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane., rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:  Elizabeth Berbakos, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850,<PHONE_NUMBER>, e-mail:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Prescription Drug Advertisements--21 CFR 202.1 (OMB Control Number
0910)--New

    Section 502(n) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 352(n)) (the act) requires that manufacturers, packers, and
distributors (sponsors) who advertise prescription human and animal
drugs, including biological products for humans, disclose in
advertisements certain information about the advertised product's uses
and risks. For prescription drugs and biologics, section 502(n) of the
act requires advertisements to contain ``a true statement'' of certain
information including ``information in brief summary relating to side
effects, contraindications, and effectiveness'' as required by
regulations issued by FDA. FDA's prescription drug advertising
regulations at Sec.  202.1 (21 CFR 202.1) describe requirements and
standards for print and broadcast advertisements. Section 202.1 applies
to advertisements published in journals, magazines, other periodicals,
and newspapers, and advertisements broadcast through media such as
radio, television, and telephone communication systems. Print
advertisements must include a brief summary of each of the risk
concepts from the product's approved package labeling (Sec.
202.1(e)(1)). Advertisements that are broadcast through media such as
television, radio, or telephone communications systems must disclose
the major risks from the product's package labeling in either the audio
or audio and visual parts of the presentation (Sec.  202.1(e)(1)); this
disclosure is known as the ``major statement.'' If a broadcast
advertisement omits the major statement, or if the major statement
minimizes the risks associated with the use of the drug, the
advertisement could render the drug misbranded in violation of the act
(21 U.S.C. 352(n) and 321(n)), and FDA's implementing regulations at
Sec.  202.1(e).
    Advertisements subject to the requirements at Sec.  202.1 are
subject to the PRA because these advertisements disclose information to
the public. In addition, Sec.  202.1(e)(6) and (j) include provisions
that are subject to OMB approval under the PRA. The information
collection requirements in Sec.  202.1 have not previously been
submitted to OMB for approval. With this notice, we are seeking comment
on the proposed information collection.
Reporting to FDA
    Section 202.1(e)(6) includes a provision that is subject to the
PRA. Section 202.1(e)(6) permits a person who would be adversely
affected by the enforcement of a provision of Sec.  202.1(e)(6) to
request a waiver from FDA for that provision. The waiver request must
set forth clearly and concisely the petitioner's interest in the
advertisement, the specific provision of Sec.  202.1(e)(6) from which a
waiver is sought, a complete copy of the

advertisement, and a showing that the advertisement is not false,
lacking in fair balance or otherwise misleading, or otherwise violative
of section 502(n) of the act.
    FDA has not received any waiver requests under Sec.  202.1(e)(6) in
the past 10 years. However, we estimate for the purposes of this
information collection that FDA would receive one waiver request
annually under Sec.  202.1(e)(6). The hours per response is the
estimated time that a respondent would spend preparing information to
be submitted to FDA under Sec.  202.1(e)(6). Based on its experience
reviewing other waiver requests, FDA estimates that approximately 12
hours on average would be needed per submission, including the time it
takes to prepare, assemble, and copy the necessary information.
    Section 202.1(j), which sets forth requirements for the
dissemination of advertisements subject to the standards in Sec.
202.1(e), contains the following information collection that is subject
to the PRA:
    Under Sec.  202.1(j)(1), a sponsor must submit advertisements to
FDA for prior approval before dissemination if: (1) The sponsor or FDA
has received information that has not been widely publicized in medical
literature that the use of the drug may cause fatalities or serious
damage; (2) FDA has notified the sponsor that the information must be
part of the advertisements for the drug; and (3) the sponsor has failed
to present to FDA a program for assuring that such information will be
publicized promptly and adequately to the medical profession in
subsequent advertisements, or if such a program has been presented to
FDA but is not being followed by the sponsor. Under Sec.
202.1(j)(1)(iii), a sponsor must provide to FDA a program for assuring
that significant new adverse information about the drug that becomes
known (i.e., use of drug may cause fatalities or serious damage) will
be publicized promptly and adequately to the medical profession in any
subsequent advertisements.
    Under Sec.  202.1(j)(4), a sponsor may voluntarily submit
advertisements to FDA for comment prior to publication.
    FDA has not received any advertisements requiring prior approval
under Sec.  202.1(j)(1) in the past 10 years. However, we estimate for
the purposes of this information collection that FDA would receive one
advertisement requiring prior approval annually under Sec.
202.1(j)(1). The hours per response is the estimated time that a
respondent would spend preparing information to be submitted to FDA
under Sec.  202.1(j)(1). Based on its experience reviewing other
advertisements, FDA estimates that approximately 2 hours on average
would be needed per submission, including the time it takes to prepare,
assemble, and copy the necessary information.
    FDA has not received any program information required under Sec.
202.1(j)(1)(iii) in the past 10 years. However, we estimate for the
purposes of this information collection that FDA would receive one
submission of program information annually under Sec.
202.1(j)(1)(iii). The hours per response is the estimated time that a
respondent would spend preparing information to be submitted to FDA
under Sec.  202.1(j)(1)(iii). Based on its experience reviewing
advertisement-related information, FDA estimates that approximately 12
hours on average would be needed per submission, including the time it
takes to prepare, assemble, and copy the necessary information.
    Based on FDA data, the Center for Drug Evaluation and Research
(CDER) estimates that approximately 1,150 draft promotional pieces are
received from approximately 125 companies annually for agency comment
prior to publication under Sec.  202.1(j)(4), the Center for Biologics
Evaluation and Research (CBER) estimates that approximately 250 draft
promotional pieces are received from approximately 25 companies
annually under Sec.  202.1(j)(4), and the Center for Veterinary
Medicine (CVM) estimates that approximately 5 draft promotional pieces
are received from approximately 5 companies annually under Sec.
202.1(j)(4). FDA anticipates that this submission rate will moderately
increase in the near future. The estimated total number of submissions
under Sec.  202.1(j)(4) is 1,405. The hours per response is the
estimated time that a respondent would spend preparing the information
to be submitted to FDA under Sec.  202.1(j)(4). Based on its experience
reviewing advertisements submitted prior to publication for agency
comment, FDA estimates that approximately 20 hours on average would be
needed per submission, including the time it takes to prepare,
assemble, and copy the necessary information.
Disclosures to the Public
    Under Sec.  202.1, advertisements for human and animal prescription
drug and biological products must comply with the standards described
in that section.
    Based on FDA data, CDER estimates that approximately 15,000
advertisements for prescription drugs, including print and broadcast
advertisements, are prepared by approximately 300 companies under Sec.
202.1 annually, CBER estimates that approximately 1,000 of these
advertisements are prepared by approximately 30 companies annually, and
CVM estimates that approximately 800 of these advertisements are
prepared by approximately 25 companies annually. FDA anticipates that
this estimate will moderately increase in the near future. The
estimated total number of advertisements under Sec.  202.1 is 16,800.
The hours per response is the estimated time that a respondent would
spend preparing an advertisement subject to Sec.  202.1. Based on its
experience reviewing advertisements, FDA estimates that approximately
400 hours on average would be needed per advertisement, including the
time it takes to prepare, assemble, and copy the necessary information.
    Under Sec.  202.1, if information that the use of a prescription
drug may cause fatalities or serious damage has not been widely
publicized in the medical literature, a sponsor must include such
information in the advertisements for that drug. FDA is not aware of
any advertisements that required inclusion of information on fatalities
or serious damage associated with use of the drug under Sec.
202.1(j)(1) in the past 10 years. However, we estimate for the purposes
of this information collection that one advertisement would require
inclusion of such information annually under Sec.  202.1(j)(1). The
hours per response is the estimated time that a respondent would spend
preparing information to comply with Sec.  202.1(j)(1). Based on its
experience reviewing changes to advertisements, FDA estimates that
approximately 40 hours on average would be needed to comply with Sec.
202.1(j)(1), including the time it takes to prepare the necessary
information.
    FDA estimates the burden of this collection of information as
follows:

                                 Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
  21 CFR     Type of        No. of       Annual Frequency  per   Total Annual     Hours  per
 Section    Submission    Respondents          Response            Responses       Response        Total Hours
----------------------------------------------------------------------------------------------------------------
202.1(e)(  Waiver                    1                   1                   1              12                12
 6)         request to
            FDA
----------------------------------------------------------------------------------------------------------------
202.1(j)(  Submission                1                   1                   1               2                 2
 1)         of
            advertisem
            ent to FDA
            for prior
            approval
----------------------------------------------------------------------------------------------------------------
202.1(j)(  Providing a               1                   1                   1              12                12
 1)(iii)    program to
            FDA for
            assuring
            that
            adverse
            informatio
            n about
            the drug
            will be
            publicized
----------------------------------------------------------------------------------------------------------------
202.1(j)(  Voluntarily             155                   9.065           1,405              20            28,100
 4)         submitting
            the
            advertisem
            ent to FDA
            prior to
            publicatio
            n for
            comment
----------------------------------------------------------------------------------------------------------------
Total                                                                                28,126
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

                                               Table 2.--Estimated Annual Third Party Disclosure Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           No. of        Annual Frequency       Total Annual        Hours per
      21 CFR Section           Type of  Submission       Respondents      per Disclosure         Disclosures       Disclosure          Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
202.1                      Advertisements prepared in             355                47.324              16,800             400                6,720,000
                            accordance with Sec.
                            202.1
--------------------------------------------------------------------------------------------------------------------------------------------------------
202.1(j)(1)                Including information                    1                 1                       1              40                       40
                            about the drug's
                            fatalities or serious
                            damage in the
                            advertisement
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total                                                                                6,720,040
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

    Dated: March 12, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-5812 Filed 3-16-10; 8:45 am]
BILLING CODE 4160-01-S


[Federal Register: October 7, 2009 (Volume 74, Number 193)]
[Notices]
[Page 51596]
[DOCID:fr07oc09-60]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2008-0683; FRL-8794-3]

FIFRA Scientific Advisory Panel; Notice of Change to Public
Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: EPA issued a notice in the Federal Register of September 16,
2009, concerning a 4-day consultation meeting of the FIFRA Scientific
Advisory Panel to consider and review a set of scientific issues
related to the assessment of hazard and exposure associated with
nanosilver and other nanometal pesticide products. This document is
being issued to revise the times for the meetings.

DATES: The consultation meeting will be held Tuesday, November 3, 2009
from approximately 1:30 p.m. to 5 p.m.; and Wednesday thru Friday,
November 4 - 6, 2009 from approximately 8:30 a.m. to 5 p.m. (eastern
time).

FOR FURTHER INFORMATION CONTACT: Joseph E. Bailey, Designated Federal
Official, Office of Science Coordination and Policy (7201M),
Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>; e-mail
address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

    The Agency included in the original notice a list of those who may
be potentially affected by this action. If you have questions regarding
the applicability of this action to a particular entity, consult the
person listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Copies of this Document and Other Related Information?

    1. Docket. EPA has established a docket for this action under
docket identification (ID) number EPA-HQ-OPP-2008-0683. Publicly
available docket materials are available either in the electronic
docket at http://www.regulations.gov, or, if only available in hard
copy, at the Office of Pesticide Programs (OPP) Regulatory Public
Docket in Rm. S-4400, One Potomac Yard (South Bldg.), 2777 S. Crystal
Dr., Arlington, VA. The hours of operation of this Docket Facility are
from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal
holidays. The Docket Facility telephone number is<PHONE_NUMBER>.
    2. Electronic access. You may access this Federal Register document
electronically through the EPA Internet under the ``Federal Register''
listings at http://www.epa.gov/fedrgstr.

II. What Does this Notice Do?

    The notice changes the time for a FIFRA Scientific Advisory Panel
meeting to consider and review a set of scientific issues related to
the assessment of hazard and exposure associated with nanosilver and
other nanometal pesticide products. The meeting announcement was
published in the Federal Register of September 16, 2009. The meeting
was originally scheduled for November 3, 2009 through November 6, 2009
and was to begin at 8:30 a.m. The time for the November 3, 2009 meeting
has been changed from 8:30 a.m. - 5 p.m. to 1:30 p.m. to 5 p.m.
(eastern time). All of the other information concerning the November 3,
as well as the November 4 - 6, 2009 meeting remains the same.

List of Subjects

    Environmental protection, Pesticides and pests.

    Dated: September 30, 2009.
Frank Sanders,
Director, Office of Science Coordination and Policy.

[FR Doc. E9-24195 Filed 10-6-09; 8:45 am]

BILLING CODE 6560-50-S


[Federal Register: April 17, 2006 (Volume 71, Number 73)]
[Proposed Rules]
[Page 19674-19675]
[DOCID:fr17ap06-25]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

[EPA-R06-OAR-2005-LA-0004; FRL-8158-9]

Approval of the Clean Air Act Section 112(l) Program for
Hazardous Air Pollutants and Delegation of Authority to the State of
Louisiana

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

-----------------------------------------------------------------------

SUMMARY: The Louisiana Department of Environmental Quality (LDEQ) has
submitted a request for receiving delegation of EPA authority for
implementation and enforcement of National Emission Standards for
Hazardous Air Pollutants (NESHAPs) for all sources (both part 70 and
non-part 70 sources). The requests apply to certain NESHAPs promulgated
by EPA, as adopted by LDEQ through July 1, 2004 (40 CFR part 63
standards). The delegation of authority under this action does not
apply to sources located in Indian Country. EPA is providing notice
that proposes to approve the delegation of certain NESHAPs to LDEQ.

DATES: Written comments must be received on or before May 17, 2006.

ADDRESSES: Comments may be mailed to Mr. Jeff Robinson, Air Permits
Section (6PD-R), Environmental Protection Agency, 1445 Ross Avenue,
Suite 1200, Dallas, Texas 75202-2733. Comments may also be submitted
electronically or through hand delivery/courier by following the
detailed instructions in the Addresses section of the direct final rule
located in the final rules section of the Federal Register.

FOR FURTHER INFORMATION CONTACT: Mr. Jeff Robinson, Air Permits
Section, Multimedia Planning and Permitting Division (6PD-R), U.S.
Environmental Protection Agency, Region 6, 1445 Ross Avenue, Suite 700,
Dallas, Texas 75202-2733, at<PHONE_NUMBER>, or at
<EMAIL_ADDRESS>

SUPPLEMENTARY INFORMATION: In the final rules section of this Federal
Register, EPA is approving LDEQ's request for delegation of authority
to implement and enforce certain NESHAPs for all sources (both part 70
and non-part 70 sources). LDEQ has adopted certain NESHAPs into
Louisiana's state regulations. In addition, EPA is waiving its
notification requirements so sources will only need to send
notifications and reports to LDEQ.
    The EPA is taking direct final action without prior proposal
because EPA views this as a non-controversial action and anticipates no
adverse comments. A detailed rationale for this approval is set forth
in the preamble to the direct final rule. If no adverse comments are
received in response to this action rule, no further activity is
contemplated. If EPA receives adverse comments, the direct final rule
will be withdrawn, and all public comments received will be addressed
in a subsequent final rule based on this proposed rule. EPA will not
institute a second comment period on this action. Any parties
interested in commenting must do so at this time. Please note that if
EPA receives adverse comment on an amendment, paragraph, or section of
this rule and if that provision may be severed from the remainder of
the rule, EPA may adopt as final those provisions of the rule that are
not the subject of an adverse comment. For additional information, see
the direct final rule which is published in the Rules section of this
Federal Register.

    Authority: 42 U.S.C. 7412.

    Dated: April 7, 2006.
Richard E. Greene,
Regional Administrator, Region 6.
[FR Doc. 06-3636 Filed 4-14-06; 8:45 am]

BILLING CODE 6560-50-P


[Federal Register Volume 88, Number 213 (Monday, November 6, 2023)]
[Proposed Rules]
[Pages 76147-76150]
[FR Doc No: 2023-24300]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2023-2144; Project Identifier MCAI-2023-00898-T]
RIN 2120-AA64

Airworthiness Directives; Airbus SAS Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: The FAA proposes to supersede Airworthiness Directive (AD)
2018-14-09, which applies to certain Airbus SAS Model A318 series
airplanes; Model A319 series airplanes; Model A320-211, -212, -214, -
216, -231, -232, and -233 airplanes; and Model A321-111, -112, -131, -
211, -212, -213, -231, and -232 airplanes. AD 2018-14-09 requires
repetitive inspections for cracking of the fastener holes in certain
fuselage frames, and depending on airplane configuration, provides an
optional terminating action to the repetitive inspections. Since the
FAA issued AD 2018-14-09, it was determined that additional actions are
necessary beyond those required by AD 2018-14-09. This proposed AD
would continue to require the actions in AD 2018-14-09 and would
require modified compliance times, as well as further inspections and
optional terminating actions for certain airplanes, as specified in a
European Union Aviation Safety Agency (EASA) AD, which is proposed for
incorporation by reference (IBR). The FAA is proposing this AD to
address the unsafe condition on these products.

DATES: The FAA must receive comments on this proposed AD by December
21, 2023.

ADDRESSES: You may send comments, using the procedures found in 14 CFR
11.43 and 11.45, by any of the following methods:
     Federal eRulemaking Portal: Go to regulations.gov. Follow
the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE, Washington, DC 20590.
     Hand Delivery: Deliver to Mail address above between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays.
    AD Docket: You may examine the AD docket at regulations.gov under
Docket No. FAA-2023-2144; or in person at Docket Operations between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD
docket contains this NPRM, the mandatory continuing airworthiness
information (MCAI), any comments received, and other information. The
street address for Docket Operations is listed above.
    Material Incorporated by Reference:
     For the EASA AD identified in this NPRM, contact EASA,
Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; telephone +49 221 8999
000; email [email protected]; website easa.europa.eu. You may find
this material on the EASA website at ad.easa.europa.eu. It is also
available at regulations.gov under Docket No. FAA-2023-2144.
     You may view this material at the FAA, Airworthiness
Products Section, Operational Safety Branch, 2200 South 216th St., Des
Moines, WA. For information on the availability of this material at the
FAA, call<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Timothy Dowling, Aviation Safety
Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590;
telephone<PHONE_NUMBER>; email [email protected].

SUPPLEMENTARY INFORMATION:

Comments Invited

    The FAA invites you to send any written relevant data, views, or
arguments about this proposal. Send your comments to an address listed
under ADDRESSES. Include ``Docket No. FAA-2023-2144; Project Identifier
MCAI-2023-00898-T'' at the beginning of your comments. The most helpful
comments reference a specific portion of the proposal, explain the
reason for any recommended change, and include supporting data. The FAA
will consider all comments received by the closing date and may amend
this proposal because of those comments.
    Except for Confidential Business Information (CBI) as described in
the following paragraph, and other information as described in 14 CFR
11.35, the FAA will post all comments received, without change, to
regulations.gov, including any personal information you provide. The
agency will also post a report summarizing each substantive verbal
contact received about this NPRM.

Confidential Business Information

    CBI is commercial or financial information that is both customarily
and actually treated as private by its owner. Under the Freedom of
Information Act (FOIA) (5 U.S.C. 552), CBI is exempt from public
disclosure. If your comments responsive to this NPRM contain commercial
or financial information that is customarily treated as private, that
you actually treat as private, and that is relevant or responsive to
this NPRM, it is important that you clearly designate the submitted
comments as CBI. Please mark each page of your submission containing
CBI as ``PROPIN.'' The FAA will treat such marked submissions as
confidential under the FOIA, and they will not be placed in the public
docket of this NPRM. Submissions containing CBI should be sent to
Timothy Dowling, Aviation Safety Engineer, FAA, 1600 Stewart Avenue,
Suite 410, Westbury, NY 11590; telephone<PHONE_NUMBER>; email
[email protected]. Any commentary that the FAA receives which
is not specifically designated as CBI will be placed in the public
docket for this rulemaking.

Background

    The FAA issued AD 2018-14-09, Amendment 39-19329 (83 FR 34034, July
19, 2018) (AD 2018-14-09), for certain Airbus SAS Model A318 series
airplanes; Model A319 series airplanes; Model A320-211, -212, -214, -
216, -231, -232, and -233 airplanes; and Model A321-111, -112, -131, -
211, -212, -213, -231, and -232 airplanes. AD 2018-14-09 was prompted
by an MCAI originated by EASA, which is the Technical Agent for the
Member States of the European Union. EASA issued AD 2016-0139, dated
July 14, 2016, to correct an unsafe condition.
    AD 2018-14-09 requires repetitive inspections for cracking of the
fastener holes in certain fuselage frames, and depending on airplane
configuration, provides an optional terminating action to the
repetitive inspections. The FAA

issued AD 2018-14-09 to address cracking at two upper rows of fasteners
of the crossbeam splicing at frame (FR)16 and FR20, on both the left-
hand (LH) and right-hand (RH) sides, which can result in reduced
structural integrity of the airplane due to the failure of structural
components.

Actions Since AD 2018-14-09 Was Issued

    Since the FAA issued AD 2018-14-09, EASA superseded AD 2016-0139,
dated July 14, 2016, and issued EASA AD 2023-0150, dated July 20, 2023
(EASA AD 2023-0150) (also referred to as the MCAI), to correct an
unsafe condition for Airbus SAS A318-111, A318-112, A318-121, A318-122,
A319-111, A319-112, A319-113, A319-114, A319-115, A319-131, A319-132,
A319-133, A320-211, A320-212, A320-214, A320-215, A320-216, A320-231,
A320-232, A320-233, A321-111, A321-112, A321-131, A321-211, A321-212,
A321-213, A321-231 and A321-232 airplanes, all manufacturer serial
numbers, except airplanes on which Airbus modification (mod) 161255 was
embodied in production, Model A318 airplanes on which Airbus mod 39195
was embodied in production, or Airbus Service Bulletin A320-00-1219 was
embodied in service; and Model A319 airplanes on which Airbus mod
28238, mod 28162, and mod 28342 were embodied in production. Model
A320-215 airplanes are not certificated by the FAA and are not included
on the U.S. type certificate data sheet; this proposed AD therefore
does not include those airplanes in the applicability. The MCAI states
that repetitive inspections were instituted due to reports of cracks on
the four holes of the crossbeam splicing at FR16 and FR20 on both LH
and RH sides. Following further assessments, the need was determined
for additional inspections, reduced compliance times, and an additional
terminating action option.
    For the reasons described above, this proposed AD retains the
requirements of AD 2018-14-09 (which corresponds to EASA AD 2016-0139),
introduces new compliance times for airplanes that embody Airbus mod
20416 or mod 21999, expands the inspection area for airplanes that
embody neither Airbus mod 20416 nor mod 21999, and adds a terminating
action option.
    The FAA is proposing this AD to address cracking at two upper rows
of fasteners of the crossbeam splicing at FR16 and FR20, on both the LH
and RH sides, which can result in reduced structural integrity of the
airplane due to the failure of structural components. You may examine
the MCAI in the AD docket at regulations.gov under Docket No. FAA-2023-
2144.

Explanation of Retained Requirements

    Although this proposed AD does not explicitly restate the
requirements of AD 2018-14-09, this proposed AD would retain all of the
requirements of AD 2018-14-09. Those requirements are referenced in
EASA AD 2023-0150, which, in turn, is referenced in paragraph (g) of
this proposed AD.

Related Service Information Under 1 CFR Part 51

    EASA AD 2023-0150 specifies procedures for repetitive rototest
inspections for cracking of the holes in certain fuselage frames and
crossbeams and applicable corrective actions (including repairing
cracking and replacing fasteners); and, for certain airplanes,
procedures for modifying the airplane, including cold working
instructions in certain fuselage frames and crossbeams, which would
terminate the inspections (optional terminating action). This material
is reasonably available because the interested parties have access to
it through their normal course of business or by the means identified
in the ADDRESSES section.

FAA's Determination

    This product has been approved by the aviation authority of another
country and is approved for operation in the United States. Pursuant to
the FAA's bilateral agreement with this State of Design Authority, it
has notified the FAA of the unsafe condition described in the MCAI
referenced above. The FAA is issuing this NPRM after determining that
the unsafe condition described previously is likely to exist or develop
in other products of the same type design.

Proposed AD Requirements in This NPRM

    This proposed AD would retain all requirements of AD 2018-14-09.
This proposed AD would require accomplishing the actions specified in
EASA AD 2023-0150 described previously, except for any differences
identified as exceptions in the regulatory text of this proposed AD and
except as discussed under ``Differences Between this Proposed AD and
the MCAI.''

Explanation of Required Compliance Information

    In the FAA's ongoing efforts to improve the efficiency of the AD
process, the FAA developed a process to use some civil aviation
authority (CAA) ADs as the primary source of information for compliance
with requirements for corresponding FAA ADs. The FAA has been
coordinating this process with manufacturers and CAAs. As a result, the
FAA proposes to incorporate EASA AD 2023-0150 by reference in the FAA
final rule. This proposed AD would, therefore, require compliance with
EASA AD 2023-0150 in its entirety through that incorporation, except
for any differences identified as exceptions in the regulatory text of
this proposed AD. Using common terms that are the same as the heading
of a particular section in EASA AD 2023-0150 does not mean that
operators need comply only with that section. For example, where the AD
requirement refers to ``all required actions and compliance times,''
compliance with this AD requirement is not limited to the section
titled ``Required Action(s) and Compliance Time(s)'' in EASA AD 2023-
0150. Service information required by EASA AD 2023-0150 for compliance
will be available at regulations.gov under Docket No. FAA-2023-2144
after the FAA final rule is published.

Differences Between This Proposed AD and the MCAI

    Although the applicability of EASA AD 2023-0150 references Airbus
Service Bulletin A320-00-1219, the FAA contacted Airbus and learned
that the referenced service information has not been published.
Therefore, this proposed AD does not include that service information
in the applicability.
    Where the service information referenced in paragraphs (8) and (9)
of EASA AD 2023-0150, i.e., ``Airbus SB A320-53-1295,'' refers to
actions when an existing hole diameter is ``more than or equal to the
minimum starting hole diameter,'' paragraph (h)(6) of this proposed AD
specifies to replace those words with ``more than or equal to the
maximum starting hole diameter.'' In Airbus Operators Information Telex
(OIT) 15-0097, Revision 01, dated January 7, 2016, Airbus confirmed
that the corrective action in Airbus Service Bulletin A320-53-1295 that
refers to ``more than or equal to the minimum starting hole diameter''
should be ``more than or equal to the maximum starting hole diameter.''
As explained in the ``Request to Include Corrections to Service
Information'' paragraph in AD 2018-14-09, Airbus released OIT 15-0097,
Revision 01, dated January 7, 2016, to correct discrepancies in Airbus
Service Bulletin A320-53-1295, which is referred to paragraphs (k) and
(m) of AD 2018-14-09. The FAA added paragraph (r) to AD 2018-14-09 to
address the diameter hole discrepancy.

Paragraphs (k) and (m) of AD 2018-14-09 correspond to paragraphs (8)
and (9) of EASA AD 2023-0150. Paragraph (r) of AD 2018-14-09
corresponds to paragraph (h)(6) of this proposed AD.
    Where rows B and C of the ``Threshold'' column in Table 1 of EASA
AD 2023-0150 refer to ``54 800 FH,'' for this proposed AD, those words
should be replaced with ``54 900 FH'' because the existing flight-hour
interval specified in Table 1 of AD 2018-14-09 is 54,900 flight hours.
Once the initial inspection is done within the ``Threshold'' compliance
times in Table 1 of EASA AD 2023-0150, the new repetitive flight-hour
interval will be 54,800 flight hours (flight-hour component only; the
complete new interval is 27,400 flight cycles or 54,800 flight hours,
whichever occurs first). The FAA has included this exception in
paragraph (h)(3) of the proposed AD.

Costs of Compliance

    The FAA estimates that this AD, if adopted as proposed, would
affect 1,680 airplanes of U.S. registry. The FAA estimates the
following costs to comply with this proposed AD:

                                      Estimated Costs for Required Actions
----------------------------------------------------------------------------------------------------------------
                                                                                Cost on U.S.
              Action                    Labor cost           Parts cost      Cost per product      operators
----------------------------------------------------------------------------------------------------------------
Retained actions from AD 2018-14-  31 work-hours x $85                  $0             $2,635         $4,426,800
 09.                                per hour = $2,635.
----------------------------------------------------------------------------------------------------------------

                  Estimated Costs for Optional Actions
------------------------------------------------------------------------
           Labor cost                 Parts cost       Cost per product
------------------------------------------------------------------------
28 work-hours x $85 per hour =               $3,020              $5,400
 $2,380.........................
------------------------------------------------------------------------

    The FAA estimates the following costs to do any necessary on-
condition actions that would be required based on the results of any
required or optional actions. The FAA has no way of determining the
number of aircraft that might need this on-condition action:

              Estimated Costs of On-Condition Replacements
------------------------------------------------------------------------
           Labor cost                 Parts cost       Cost per product
------------------------------------------------------------------------
14 work-hours x $85 per hour =                  $50              $1,240
 $1,190.........................
------------------------------------------------------------------------

    The FAA has received no definitive data that would enable us to
provide cost estimates for the on-condition repairs specified in this
proposed AD.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. Subtitle VII: Aviation Programs,
describes in more detail the scope of the Agency's authority.
    The FAA is issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701: General requirements.
Under that section, Congress charges the FAA with promoting safe flight
of civil aircraft in air commerce by prescribing regulations for
practices, methods, and procedures the Administrator finds necessary
for safety in air commerce. This regulation is within the scope of that
authority because it addresses an unsafe condition that is likely to
exist or develop on products identified in this rulemaking action.

Regulatory Findings

    The FAA determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national Government and the States, or on the distribution
of power and responsibilities among the various levels of government.
    For the reasons discussed above, I certify this proposed
regulation:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,
    (2) Would not affect intrastate aviation in Alaska, and
    (3) Would not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority:  49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. The FAA amends Sec.  39.13 by:
0
a. Removing Airworthiness Directive (AD) 2018-14-09, Amendment 39-19329
(83 FR 34034, July 19, 2018); and
0
b. Adding the following new AD:

Airbus SAS: Docket No. FAA-2023-2144; Project Identifier MCAI-2023-
00898-T.

(a) Comments Due Date

    The FAA must receive comments on this airworthiness directive
(AD) by December 21, 2023.

(b) Affected ADs

    This AD replaces AD 2018-14-09, Amendment 39-19329 (83 FR 34034,
July 19, 2018) (AD 2018-14-09).

(c) Applicability

    This AD applies to Airbus SAS Model A318-111, -112, -121, and -
122 airplanes; Model A319-111, -112, -113, -114, -115, -131, -132,
and -133 airplanes; Model A320-211, -212, -214, -216, -231, -232,
and -233 airplanes; and Model A321-111, -112, -131, -211, -212, -
213, -231, and -232 airplanes; certificated in any category, all

manufacturer serial numbers, except the airplanes specified in
paragraphs (c)(1) through (3) of this AD.
    (1) Airplanes on which Airbus modification 161255 has been
embodied in production.
    (2) Model A319 series airplanes on which Airbus modifications
28238, 28162, and 28342 have been concurrently embodied in
production.
    (3) Model A318 series airplanes on which Airbus modification
39195 has been embodied in production.

(d) Subject

    Air Transport Association (ATA) of America Code 53, Fuselage.

(e) Unsafe Condition

    This AD was prompted by reports of early cracking on the four
holes of the crossbeam splicing at certain fuselage frames (FR). The
FAA is issuing this AD to address cracking at two upper rows of
fasteners of the crossbeam splicing at FR16 and FR20, on both the
left-hand (LH) and right-hand (RH) sides. The unsafe condition, if
not addressed, could result in reduced structural integrity of the
airplane due to the failure of structural components.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Requirements

    Except as specified in paragraph (h) of this AD: Comply with all
required actions and compliance times specified in, and in
accordance with, European Union Aviation Safety Agency (EASA) AD
2023-0150, dated July 20, 2023 (EASA AD 2023-0150).

(h) Exceptions to EASA AD 2023-0150

    (1) Where EASA AD 2023-0150 refers to ``28 July 2016 [the
effective date of EASA AD 2016-0139],'' this AD requires using
August 23, 2018 (the effective date of AD 2018-14-09).
    (2) Where EASA AD 2023-0150 refers to its effective date, this
AD requires using the effective date of this AD.
    (3) Where rows B and C of the ``Threshold'' column in Table 1 of
EASA AD 2023-0150 refer to ``54 800 FH,'' for this AD, replace those
words with ``54 900 FH.''
    (4) Where paragraph (5) of EASA AD 2023-0150 refers to ``valid
within the EASA system,'' for this AD, replace those words with
``approved by the FAA, EASA, Airbus's EASA Design Organization
Approval (DOA), or an EASA DOA (other than Airbus's EASA DOA).''
    (5) Where paragraph (5) of EASA AD 2023-0150 specifies ``contact
that design approval holder (DAH) for assessment and repair
instructions, obtain EASA AMOC approval and accomplish those
instructions accordingly, as applicable,'' for this AD, replace
those words with ``modify the repair using a method approved by the
Manager, International Validation Branch, FAA; or EASA; or Airbus's
EASA DOA. If approved by the DOA, the approval must include the DOA-
authorized signature.''
    (6) Where the service information referenced in paragraphs (8)
and (9) of EASA AD 2023-0150 refers to actions when an existing hole
diameter is ``more than or equal to the minimum starting hole
diameter,'' for this AD, replace those words with ``more than or
equal to the maximum starting hole diameter.''
    (7) This AD does not adopt the ``Remarks'' section of EASA AD
2023-0150.

(i) No Reporting Requirement

    Although the service information referenced in EASA AD 2023-0150
specifies to submit certain information to the manufacturer, this AD
does not include that requirement.

(j) Additional AD Provisions

    The following provisions also apply to this AD:
    (1) Alternative Methods of Compliance (AMOCs): The Manager,
International Validation Branch, FAA, has the authority to approve
AMOCs for this AD, if requested using the procedures found in 14 CFR
39.19. In accordance with 14 CFR 39.19, send your request to your
principal inspector or responsible Flight Standards Office, as
appropriate. If sending information directly to the International
Validation Branch, send it to the attention of the person identified
in paragraph (k) of this AD. Information may be emailed to: [email protected]. Before using any approved AMOC, notify your
appropriate principal inspector, or lacking a principal inspector,
the manager of the responsible Flight Standards Office.
    (2) Contacting the Manufacturer: For any requirement in this AD
to obtain instructions from a manufacturer, the instructions must be
accomplished using a method approved by the Manager, International
Validation Branch, FAA; or EASA; or Airbus SAS's EASA Design
Organization Approval (DOA). If approved by the DOA, the approval
must include the DOA-authorized signature.
    (3) Required for Compliance (RC): Except as required by
paragraphs (i) and (j)(2) of this AD, if any service information
contains procedures or tests that are identified as RC, those
procedures and tests must be done to comply with this AD; any
procedures or tests that are not identified as RC are recommended.
Those procedures and tests that are not identified as RC may be
deviated from using accepted methods in accordance with the
operator's maintenance or inspection program without obtaining
approval of an AMOC, provided the procedures and tests identified as
RC can be done and the airplane can be put back in an airworthy
condition. Any substitutions or changes to procedures or tests
identified as RC require approval of an AMOC.

(k) Additional Information

    For more information about this AD, contact Timothy Dowling,
Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410,
Westbury, NY 11590; telephone<PHONE_NUMBER>; email
[email protected].

(l) Material Incorporated by Reference

    (1) The Director of the Federal Register approved the
incorporation by reference (IBR) of the service information listed
in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.
    (2) You must use this service information as applicable to do
the actions required by this AD, unless this AD specifies otherwise.
    (i) European Union Aviation Safety Agency (EASA) AD 2023-0150,
dated July 20, 2023.
    (ii) [Reserved]
    (3) For EASA AD 2023-0150, contact EASA, Konrad-Adenauer-Ufer 3,
50668 Cologne, Germany; telephone +49 221 8999 000; email
[email protected]; website easa.europa.eu. You may find this EASA
AD on the EASA website at ad.easa.europa.eu.
    (4) You may view this service information at the FAA,
Airworthiness Products Section, Operational Safety Branch, 2200
South 216th St., Des Moines, WA. For information on the availability
of this material at the FAA, call<PHONE_NUMBER>.
    (5) You may view this material at the National Archives and
Records Administration (NARA). For information on the availability
of this material at NARA, visit www.archives.gov/federal-register/cfr/ibr-locations or email [email protected].

    Dated: Issued on October 30, 2023.
Victor Wicklund,
Deputy Director, Compliance & Airworthiness Division, Aircraft
Certification Service.
[FR Doc. 2023-24300 Filed 11-3-23; 8:45 am]
BILLING CODE 4910-13-P